Chairs: Michael Hofman & Mike Sathekge
Re-assessing gallium-67 as a therapeutic radionuclide (#26)
1:30 PM
177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy and quality of life assessment. (#27)
1:45 PM
Initial experience with aggressive treatment of metastastic prostate cancer using 3 cycles of 7.4 GBq [177Lu]-PSMA every 4 weeks (#28)
2:00 PM
Theranostic in early detection of recurring prostate cancer: 64CuCl2 (#29)
2:15 PM